Selected research
Industry Research
NGS for Cancer Early Screening Industry Research Report 2026
Market perspective
The global NGS for Cancer Early Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the NGS for Cancer Early Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the NGS for Cancer Early Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the NGS for Cancer Early Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of NGS for Cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global NGS for Cancer Early Screening market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to NGS for Cancer Early Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NGS for Cancer Early Screening Market by Company
Guardant Health
Exact Sciences
Freenome
Epiginomics AG
Bio-techne
ThriveEarlier Detection
GRAIL, Inc.
CellMax life
Berry Genomics
Singlera Genomics
Geneseeq
BGI Genomics
Burning Rock Biotech Limited
New Horizon Health Limited
Yeasen Bio
Hangzhou Aoru Biotech
Amoy Diagnostics Co., Ltd.
Genetron Health
AnchorDx
NGS for Cancer Early Screening Segment by Type
ctDNA Gene Mutation Detection
cfDNA Methylation Sequencing
NGS for Cancer Early Screening Segment by Application
Medical Institutions
Physical Examination Centers
NGS for Cancer Early Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS for Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NGS for Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS for Cancer Early Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of NGS for Cancer Early Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ctDNA Gene Mutation Detection
- cfDNA Methylation Sequencing
Applications
- Medical Institutions
- Physical Examination Centers
Companies covered
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 NGS for Cancer Early Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 ctDNA Gene Mutation Detection
- 2.2.3 cfDNA Methylation Sequencing
- 2.3 NGS for Cancer Early Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Medical Institutions
- 2.3.3 Physical Examination Centers
- 2.4 Assumptions and Limitations
3 NGS for Cancer Early Screening Breakdown Data by Type
- 3.1 Global NGS for Cancer Early Screening Historic Market Size by Type (2021-2026)
- 3.2 Global NGS for Cancer Early Screening Forecasted Market Size by Type (2027-2032)
4 NGS for Cancer Early Screening Breakdown Data by Application
- 4.1 Global NGS for Cancer Early Screening Historic Market Size by Application (2021-2026)
- 4.2 Global NGS for Cancer Early Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global NGS for Cancer Early Screening Market Perspective (2021-2032)
- 5.2 Global NGS for Cancer Early Screening Growth Trends by Region
- 5.2.1 Global NGS for Cancer Early Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 NGS for Cancer Early Screening Historic Market Size by Region (2021-2026)
- 5.2.3 NGS for Cancer Early Screening Forecasted Market Size by Region (2027-2032)
- 5.3 NGS for Cancer Early Screening Market Dynamics
- 5.3.1 NGS for Cancer Early Screening Industry Trends
- 5.3.2 NGS for Cancer Early Screening Market Drivers
- 5.3.3 NGS for Cancer Early Screening Market Challenges
- 5.3.4 NGS for Cancer Early Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top NGS for Cancer Early Screening Players by Revenue
- 6.1.1 Global Top NGS for Cancer Early Screening Players by Revenue (2021-2026)
- 6.1.2 Global NGS for Cancer Early Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global NGS for Cancer Early Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of NGS for Cancer Early Screening Head Office and Area Served
- 6.4 Global NGS for Cancer Early Screening Players, Product Type & Application
- 6.5 Global NGS for Cancer Early Screening Manufacturers Established Date
- 6.6 Global NGS for Cancer Early Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America NGS for Cancer Early Screening Market Size (2021-2032)
- 7.2 North America NGS for Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America NGS for Cancer Early Screening Market Size by Country (2021-2026)
- 7.4 North America NGS for Cancer Early Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe NGS for Cancer Early Screening Market Size (2021-2032)
- 8.2 Europe NGS for Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe NGS for Cancer Early Screening Market Size by Country (2021-2026)
- 8.4 Europe NGS for Cancer Early Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific NGS for Cancer Early Screening Market Size (2021-2032)
- 9.2 Asia-Pacific NGS for Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific NGS for Cancer Early Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific NGS for Cancer Early Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America NGS for Cancer Early Screening Market Size (2021-2032)
- 10.2 South America NGS for Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America NGS for Cancer Early Screening Market Size by Country (2021-2026)
- 10.4 South America NGS for Cancer Early Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa NGS for Cancer Early Screening Market Size (2021-2032)
- 11.2 Middle East & Africa NGS for Cancer Early Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Guardant Health
- 12.1.1 Guardant Health Company Information
- 12.1.2 Guardant Health Business Overview
- 12.1.3 Guardant Health Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.1.4 Guardant Health NGS for Cancer Early Screening Product Portfolio
- 12.1.5 Guardant Health Recent Developments
- 12.2 Exact Sciences
- 12.2.1 Exact Sciences Company Information
- 12.2.2 Exact Sciences Business Overview
- 12.2.3 Exact Sciences Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.2.4 Exact Sciences NGS for Cancer Early Screening Product Portfolio
- 12.2.5 Exact Sciences Recent Developments
- 12.3 Freenome
- 12.3.1 Freenome Company Information
- 12.3.2 Freenome Business Overview
- 12.3.3 Freenome Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.3.4 Freenome NGS for Cancer Early Screening Product Portfolio
- 12.3.5 Freenome Recent Developments
- 12.4 Epiginomics AG
- 12.4.1 Epiginomics AG Company Information
- 12.4.2 Epiginomics AG Business Overview
- 12.4.3 Epiginomics AG Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.4.4 Epiginomics AG NGS for Cancer Early Screening Product Portfolio
- 12.4.5 Epiginomics AG Recent Developments
- 12.5 Bio-techne
- 12.5.1 Bio-techne Company Information
- 12.5.2 Bio-techne Business Overview
- 12.5.3 Bio-techne Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.5.4 Bio-techne NGS for Cancer Early Screening Product Portfolio
- 12.5.5 Bio-techne Recent Developments
- 12.6 ThriveEarlier Detection
- 12.6.1 ThriveEarlier Detection Company Information
- 12.6.2 ThriveEarlier Detection Business Overview
- 12.6.3 ThriveEarlier Detection Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.6.4 ThriveEarlier Detection NGS for Cancer Early Screening Product Portfolio
- 12.6.5 ThriveEarlier Detection Recent Developments
- 12.7 GRAIL, Inc.
- 12.7.1 GRAIL, Inc. Company Information
- 12.7.2 GRAIL, Inc. Business Overview
- 12.7.3 GRAIL, Inc. Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.7.4 GRAIL, Inc. NGS for Cancer Early Screening Product Portfolio
- 12.7.5 GRAIL, Inc. Recent Developments
- 12.8 CellMax life
- 12.8.1 CellMax life Company Information
- 12.8.2 CellMax life Business Overview
- 12.8.3 CellMax life Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.8.4 CellMax life NGS for Cancer Early Screening Product Portfolio
- 12.8.5 CellMax life Recent Developments
- 12.9 Berry Genomics
- 12.9.1 Berry Genomics Company Information
- 12.9.2 Berry Genomics Business Overview
- 12.9.3 Berry Genomics Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.9.4 Berry Genomics NGS for Cancer Early Screening Product Portfolio
- 12.9.5 Berry Genomics Recent Developments
- 12.10 Singlera Genomics
- 12.10.1 Singlera Genomics Company Information
- 12.10.2 Singlera Genomics Business Overview
- 12.10.3 Singlera Genomics Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.10.4 Singlera Genomics NGS for Cancer Early Screening Product Portfolio
- 12.10.5 Singlera Genomics Recent Developments
- 12.11 Geneseeq
- 12.11.1 Geneseeq Company Information
- 12.11.2 Geneseeq Business Overview
- 12.11.3 Geneseeq Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.11.4 Geneseeq NGS for Cancer Early Screening Product Portfolio
- 12.11.5 Geneseeq Recent Developments
- 12.12 BGI Genomics
- 12.12.1 BGI Genomics Company Information
- 12.12.2 BGI Genomics Business Overview
- 12.12.3 BGI Genomics Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.12.4 BGI Genomics NGS for Cancer Early Screening Product Portfolio
- 12.12.5 BGI Genomics Recent Developments
- 12.13 Burning Rock Biotech Limited
- 12.13.1 Burning Rock Biotech Limited Company Information
- 12.13.2 Burning Rock Biotech Limited Business Overview
- 12.13.3 Burning Rock Biotech Limited Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.13.4 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Portfolio
- 12.13.5 Burning Rock Biotech Limited Recent Developments
- 12.14 New Horizon Health Limited
- 12.14.1 New Horizon Health Limited Company Information
- 12.14.2 New Horizon Health Limited Business Overview
- 12.14.3 New Horizon Health Limited Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.14.4 New Horizon Health Limited NGS for Cancer Early Screening Product Portfolio
- 12.14.5 New Horizon Health Limited Recent Developments
- 12.15 Yeasen Bio
- 12.15.1 Yeasen Bio Company Information
- 12.15.2 Yeasen Bio Business Overview
- 12.15.3 Yeasen Bio Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.15.4 Yeasen Bio NGS for Cancer Early Screening Product Portfolio
- 12.15.5 Yeasen Bio Recent Developments
- 12.16 Hangzhou Aoru Biotech
- 12.16.1 Hangzhou Aoru Biotech Company Information
- 12.16.2 Hangzhou Aoru Biotech Business Overview
- 12.16.3 Hangzhou Aoru Biotech Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.16.4 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Portfolio
- 12.16.5 Hangzhou Aoru Biotech Recent Developments
- 12.17 Amoy Diagnostics Co., Ltd.
- 12.17.1 Amoy Diagnostics Co., Ltd. Company Information
- 12.17.2 Amoy Diagnostics Co., Ltd. Business Overview
- 12.17.3 Amoy Diagnostics Co., Ltd. Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.17.4 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Portfolio
- 12.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
- 12.18 Genetron Health
- 12.18.1 Genetron Health Company Information
- 12.18.2 Genetron Health Business Overview
- 12.18.3 Genetron Health Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.18.4 Genetron Health NGS for Cancer Early Screening Product Portfolio
- 12.18.5 Genetron Health Recent Developments
- 12.19 AnchorDx
- 12.19.1 AnchorDx Company Information
- 12.19.2 AnchorDx Business Overview
- 12.19.3 AnchorDx Revenue in NGS for Cancer Early Screening Business (2021-2026)
- 12.19.4 AnchorDx NGS for Cancer Early Screening Product Portfolio
- 12.19.5 AnchorDx Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst